An assessment of PCV13 vaccine coverage using a repeated cross-sectional household survey in Malawi by Bondo, A et al.
Gates Open Research
 
Open Peer Review
Discuss this article
 (0)Comments
RESEARCH ARTICLE
An assessment of PCV13 vaccine coverage using a repeated
 cross-sectional household survey in Malawi [version 1; referees:
1 approved]
Austin Bondo ,         Bejoy Nambiar , Norman Lufesi , Rashid Deula , Carina King ,
       Gibson Masache , Charles Makwenda , Anthony Costello , Dale Rhoda ,
 Eric D. McCollum , Tim Colbourn 2
Parent and Child Health Initiative (PACHI) Trust, Lilongwe, Malawi
UCL Institute for Global Health, London, WC1N 1EH, UK
Acute Respiratory Infections Unit, Ministry of Health, Lilongwe, Malawi
Biostat Global Consulting, Worthington, OH, 43085, USA
Department of Pediatrics, Eudowood Division of Pediatric Respiratory Sciences, Johns Hopkins School of Medicine, Baltimore, USA
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
Abstract
The 13-valent pneumococcal conjugate vaccine (PCV13) wasBackground: 
introduced in Malawi from November 2011 using a three dose primary series at
6, 10, and 14 weeks of age to reduce  -relatedStreptococcus pneumoniae
diseases. To date, PCV13 paediatric coverage in Malawi has not been
rigorously assessed.  We used household surveys to longitudinally track
paediatric PCV13 coverage in rural Malawi.
Samples of 60 randomly selected children (30 infants aged 6 weeksMethods: 
to 4 months and 30 aged 4-16 months) were sought in each of 20 village clinic
catchment ‘basins’ of Kabudula health area, Lilongwe, Malawi between March
2012 and June 2014. Child health information was reviewed and mothers
interviewed to determine each child’s PCV13 dose status and vaccine timing.
The survey was completed six times in 4-8 month intervals. Survey inference
was used to assess PCV13 dose coverage in each basin for each age group.
All 20 basins were pooled to assess area-wide vaccination coverage over time,
by age in months, and adherence to the vaccination schedule.
We surveyed a total of 8,562 children in six surveys; 82% were in theResults: 
older age group. Overall, in age-eligible children, two-dose and three-dose
coverage increased from 30% to 85% and 10% to 86%, respectively, between
March 2012 and June 2014.  PCV13 coverage was higher in the older age
group in all surveys. Although it varied by basin, PCV13 coverage was
consistently delayed: median ages at first, second and third doses were 9, 15
and 21 weeks, respectively.
In our rural study area, PCV13 introduction did not meet theConclusion: 
Malawi Ministry of Health one-year three-dose 90% coverage target, but after 2
years reached levels likely to reduce the prevalence of both invasive and
non-invasive paediatric pneumococcal diseases. Better adherence to the
PCV13 schedule may reduce pneumococcal disease in younger Malawian
children.
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ARI	 		acute	respiratory	infection	
IPD	 		invasive	pneumococcal	disease
IQR	 		inter-quartile	range
LCB		 		lower	1-sided	95%	confidence	bound
LQAS	 		lot	quality	assurance	sampling
PCV		 		pneumococcal	conjugate	vaccine
PCV13	 		13-valent	pneumococcal	conjugate	vaccine
WHO	 		World	Health	Organisation
Introduction
Acute	 respiratory	 infection	 (ARI)	 is	 a	 leading	 cause	 of	 death	 in	
children	 aged	 0–59	months	 old	worldwide.	 Pneumonia,	 a	 severe	
form	 of	 acute	 lower	 respiratory	 infection	 that	 affects	 the	 lungs,	
claims	 around	 0.9	 million	 lives	 of	 infants	 and	 young	 children	
annually1.	 Pneumonia	 is	 more	 common	 in	 developing	 coun-
tries,	specifically	 those	 in	Africa	and	South	Asia2,3.	Streptococcus 
pneumoniae	 and	 Haemophilus influenzae	 are	 the	 most	 com-
mon	 causative	 agents	 of	 bacterial	 pneumonia	 in	 children	 and	
are	 targeted	 by	 the	 Pneumococcal	 conjugate	 vaccine	 (PCV)	
and	 the	 H. influenzae	 B	 vaccine,	 respectively2,3.	 PCV	 also	 pre-
vents	 invasive	 pneumococcal	 disease	 (IPD)4	 and	 pneumococcal	
meningitis5.	 In	 2007,	 the	 World	 Health	 Organisation	 (WHO)	
recommended	 PCV	 be	 added	 to	 all	 national	 immunization	
programmes,	especially	in	countries	with	high	child	mortality3.
Malawi	 recorded	 around	 500	ARI	 cases	 per	 1000	 under-5-years	
population	 between	 July	 2009	 and	 June	 2010,	 of	 which	
approximately	 1.5%	 died,	 according	 to	 health	 management	
information	 system	 statistics6;	 the	 death	 rate	 is	 likely	 to	 be	 an	
under-estimate,	 as	 it	 is	 based	 on	 health	 facility	 data	 only.	 In	
November	2011,	Malawi	was	among	 the	first	 countries	 in	Africa	
to	 introduce	 the	 13-valent	 Pneumococcal	 Conjugate	 Vaccine	
(PCV13)7	 into	 its	 routine	 immunization	 program,	 aiming	 to	
protect	 millions	 of	 children	 from	 pneumococcal	 pneumonia	
and	 IPD.	 The	 vaccine	 was	 introduced	 as	 a	 three-dose	 schedule	
at	 6,	 10	 and	 14	 weeks,	 with	 an	 initial	 catch-up	 campaign	
targeting	 all	 children	 up	 to	 the	 age	 of	 1	 year.	A	 target	 national	
coverage	 rate	 of	 ≥90%	 and	 local	 district	 targets	 of	 ≥80%	 were	
set	for	each	year	from	2012	to	20168.
We	used	a	 series	of	household	 surveys	 to	 assess	 changes	 in	vac-
cine	 coverage	 in	 a	 rural	 area	 of	 central	Malawi	 between	March	
2012	 and	 June	 2014.	 The	 surveys	 were	 part	 of	 a	 wider	 study	
exploring	 changes	 in	 the	 health-system	 burden	 of	 pneumonia	
following	 PCV13	 vaccination	 introduction	 in	 two	 areas	 of	 cen-
tral	Malawi9.	We	used	the	surveys	to	estimate	local	and	area-wide	
vaccination	 coverage	 in	 one	 of	 our	 study	 areas	 to	 assess	 the	
burden	 of	 pneumonia	 at	 the	 community	 health	 worker,	 health	
centre	 and	hospital	 levels	 in	 relation	 to	 the	percentage	of	 infants	
vaccinated.	 We	 aimed	 to	 quantify	 how	 the	 burden	 of	 pneu-
monia	 on	 the	 health	 system	 changed	 as	 vaccination	 coverage	
increased,	 and	 to	 track	 the	 roll-out	 of	 the	 PCV13	 vaccine	 in	
Malawi	 in	 terms	 of	 the	 timeliness	 of	 each	 of	 the	 three	 doses	 in	
relation	 to	 the	 6,	 10,	 14-week	 schedule	 and	 population	 coverage	
of	 each	 dose	 over	 time.	 In	 this	 paper	 we	 present	 the	 results	 of	
six	surveys	conducted	in	Lilongwe	district.
Methods
Setting
This	 study	 took	 place	 in	 Kabudula,	 one	 of	 six	 health	 areas	
in	 Lilongwe	 district	 of	 the	 central	 region	 of	 Malawi,	 a	 low-
income	 country	 in	 Sub-Saharan	 Africa	 with	 a	 population	 of	
approximately	 18	 million	 in	 2016	 and	 a	 GDP	 per	 capita	 of	
$1169	 (purchasing	 power	 parity	 international	 dollars,	 2016)10.	
Lilongwe	 district	 is	 socio-economically	 reflective	 of	 Malawi,	
with	 youth	 female	 literacy	 of	 72%,	 and	 net	 secondary	 school	
attendance	 of	 16%11.	 Under-5	 mortality	 is	 rapidly	 improv-
ing	 in	 Malawi	 and	 was	 estimated	 to	 be	 71	 deaths	 per	 1000	
livebirths	nationally	in	2013,	while	this	study	was	on-going12.
Sample size and data collection
We	 aimed	 to	 randomly	 sample	 30	 infants	 under	 4	 months	 and	
30	 infants	 aged	 4–16	 months	 in	 each	 of	 six	 waves	 of	 the	 sur-
vey	 in	 each	 of	 20	 village	 clinic	 catchment	 ‘basins’	 in	Kabudula.	
The	 target	 of	 30	 infants	 in	 each	 age	group	was	 chosen	based	on	
a	 lot	 quality	 assurance	 sampling	 (LQAS)	 decision	 rule	 of	 a	 cut-
off	 of	 19/30	 children	 being	 unvaccinated	 (zero	 doses)	 yielding	
optimal	 power	 to	 determine	 whether	 the	 basin	 has	 above	 50%	
PCV13	 single	 dose	 coverage	 (with	 95%	 power)	 or	 below	 25%	
(with	 89%	 power)13	 From	 the	 survey	 standpoint,	 the	 clinics	 are	
strata.	Vaccination	 coverage	 can	 be	 calculated	 in	 each	 and	 then	
the	 data	 may	 be	 pooled	 to	 calculate	 an	 overall	 Kabudula-wide	
estimate.	 The	 village	 clinics	 are	 those	 in	 Kabadula	 that	 took	
part	 in	 the	 community	 component	 of	 the	 parent	 PCV13	 vaccine	
study9.	 We	 sought	 to	 estimate	 coverage	 for	 under-4	 month-old	
and	 4–16	 month-old	 infants,	 in	 order	 to	 study	 the	 age-related	
dynamics	 of	 pneumococcal	 disease	 burden	 with	 respect	 to	
vaccine	 coverage.	 Measuring	 the	 infants	 age	 also	 enabled	 us	 to	
determine	 how	 closely	 the	 6,	 10,	 14	 week	 schedule	 was	 being	
followed.	 Timely	 vaccination	 was	 defined	 as	 per	 the	 standard	
WHO	 schedule:	 the	 first	 dose	 being	 received	 between	 4	 weeks	
and	 2	 months	 of	 age,	 the	 second	 dose	 between	 8	 weeks	 and	
4	months	and	the	third	dose	between	12	weeks	and	6	months14.
Six	 separate	 surveys	 were	 conducted	 in	 March	 2012,	 October	
2012,	 June	 2013,	 October	 2013,	 February	 2014	 and	 June	 2014	
following	the	introduction	of	the	vaccine	in	November	2011.
Surveys	 were	 conducted	 by	 12	 experienced	 data	 collectors	
and	 a	 supervisor.	 Prior	 to	 each	 survey,	 data	 collectors	 were	
given	 a	 one-day	 intensive	 training	 on	 data	 collection,	 covering	
research	 ethics	 and	 etiquette,	 interviewing	 techniques,	 and	
means	 of	 verification.	 Data	 collection	 for	 each	 survey	 lasted	 10	
days.
During	 the	 data	 collection	 exercise,	 a	 random	walk	method	was	
employed	 to	 identify	 eligible	 infants	 for	 the	 survey.	After	 arriv-
ing	 at	 the	 centre	 of	 each	 village,	 data	 collectors	 walked	 in	 a	
direction	 indicated	 by	 spinning	 a	 bottle,	 calling	 at	 every	 house	
on	 the	 way.	 At	 each	 house	 the	 data	 collector	 briefly	 explained	
that	 they	were	conducting	a	survey	 to	find	out	how	many	 infants	
had	 been	 vaccinated	 with	 PCV13.	 Then,	 they	 asked	 whether	
there	 were	 any	 infants	 aged	 between	 6	 weeks	 (old	 enough	 to	
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have	 a	 vaccination)	 and	 16	 months	 (enough	 time	 for	 a	 third	
dose	 to	 be	 given	 to	 a	 child	 who	 was	 under	 age	 1	 year	 at	 first	
dose,	 the	 initial	 ‘catch-up’	 target	 age	 group	 for	 the	 vaccination	
campaign).	 For	 respondents	 with	 infants,	 the	 data	 collec-
tor	 requested	 to	 see	 the	 infant’s	 health	 passport	 (a	 government	
provided	 health	 record)	 and	 it	 was	 inspected	 for	 vaccination	
records	 and	 date	 of	 birth.	 Old	 health	 passport	 books	 did	 not	
have	a	recording	space	for	PCV13;	in	such	cases	the	data	collec-
tor	 inspected	 all	 pages	 to	make	 sure	 that	 they	 did	 not	 miss	 any	
recorded	vaccination	data.	A	digital	photograph	or	scan	was	taken	
of	the	page	where	the	vaccination	records	were	recorded.	All	data	
from	 the	 paper	 forms	 was	 single-entered	 into	 a	 computer	 for	
analysis	 and	 the	 digital	 photographs	 (available	 for	 96%	 of	
records)	were	used	to	verify	the	entered	data.	In	the	event	that	the	
household	 did	 not	 have	 an	 eligible	 infant	 for	 the	 study,	 the	 data	
collectors	 moved	 to	 the	 next	 house	 and	 repeated	 the	 process.	
In	 cases	 where	 the	 infant	 did	 not	 have	 a	 health	 passport,	 data	
collectors	 relied	 on	 verbal	 information	 from	 the	 caregivers	
(Figure	 1).	 Data	 collection	 for	 the	 under-4-month-old	 infants	
often	 stopped	 before	 the	 target	 of	 30	was	 reached	 in	 the	 village	
clinic	 basin	 due	 to	 no	 more	 infants	 of	 this	 age	 group	 being	
found.	Additional	 infants	 in	 the	older	age	group	were	 sometimes	
surveyed	 to	 compensate.	 Both	 of	 these	 practices	 resulted	 in	
target	 sample	 sizes	 being	 missed	 for	 each	 age	 group	 for	 most	
village	basins.
Analysis
Due	 to	 considerable	 variation	 in	 the	 sample	 sizes	 obtained	 and	
our	 surveys	 often	 capturing	 a	 large	 proportion	 of	 the	 eligible	
population	 of	 children	 in	 each	 catchment	 area	 for	 each	 age-
Figure 1. Data collection flow chart.
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group	 (12–100%,	 median	 47%),	 to	 simplify	 the	 analysis	 whilst	
ensuring	 informative	 results,	we	 opted	 to	 analyse	 our	 data	 using	
survey-based	inference	rather	than	LQAS	methods.	Using	a	finite	
population	 correction	 that	 incorporated	 the	 total	 estimated	 eligi-
ble	 population,	 the	 number	 of	 infants	 surveyed	 and	 the	 number	
of	 infants	 vaccinated	 (either	 with	 one,	 two	 or	 three	 doses	 of	
PCV13)	 in	each	catchment	area	age-group	sample,	we	calculated	
one-sided	 modified	Wilson	 95%	 confidence	 intervals	 (using	 the	
lower	 95%	 confidence	 bound)15	 for	 the	 proportion	 vaccinated	
to	 estimate	 whether	 each	 age-group	 in	 each	 basin	 was	 above	
or	 below	 set	 target	 threshold	 levels	 of	 coverage	 of	 each	 dose	
of	 PCV1316.	 We	 use	 inchworm	 plots16	 to	 clearly	 visualise	 the	
confidence	 intervals	 in	 relation	 to	 the	 targets.	 If	 the	 lower	 one-
sided	95%	confidence	bound	(LCB)	was	above	the	target	we	infer	
that	the	target	was	achieved.
Overall	 percentage	 coverage	 of	 each	 PCV13	 dose	 in	 each	 age	
group	 and	 by	 age	 in	 months	 for	 all	 20	 clinic	 catchment	 areas	
combined	 was	 also	 calculated	 for	 each	 of	 the	 six	 sequential	
surveys	and	 trends	over	 time	were	visualised	and	quantified.	Our	
estimates	 of	 coverage	 of	 each	 dose	 are	 for	 age-eligible	 children,	
i.e.	 the	 denominator	 is	 all	 children	 at	 least	 6	 weeks	 (42	 days)	
old	for	the	first	dose,	all	children	at	least	10	weeks	(70	days)	old	
for	 the	second	dose,	and	all	children	at	 least	14	weeks	 (98	days)	
old	 for	 the	 third	 dose.	The	 data	 processing	 and	 graphs	 for	 these	
analyses	were	produced	using	Stata	13.1	and	Stata	14.2	for	Mac.
Ethical approval and consent
Ethical	 approval	 was	 granted	 for	 this	 study	 by	 the	 National	
Health	 Sciences	 Research	 Committee	 in	 Malawi	 (reference:	
941),	 and	 included	 approval	 for	 verbal	 consent	 to	 collect	
vaccination	 data	 from	 routine	 records	 (health	 passports).	 Verbal	
consent	was	 given	 from	all	 survey	 respondents	who	 took	 part	 in	
this	 study,	 and	was	 documented	 by	 the	 fieldworkers	 on	 the	 data	
collection	 form	 during	 data	 collection.	 The	 study	was	 explained	
to	 respondents	 before	 verbal	 consent	 was	 given	 and	 verbal	
consent	 was	 only	 deemed	 necessary	 rather	 than	 written	 consent	
given	 low	 levels	 of	 literacy	 in	 the	 population	 and	 the	 fact	 the	
study	 was	 not	 asking	 about	 sensitive	 information.	 This	 study	
involved	 collection	 of	 vaccination	 data	 on	 infants	 under	 16	
months	 old—parental	 consent	 was	 given	 for	 this	 data	 to	 be	
collected	 as	 this	data	was	 collected	 from	 the	parents	 themselves.	
This	paper	does	not	present	any	 individual	or	 identifiable	patient	
data,	therefore	consent	for	publication	is	not	applicable.
Results
Table	 1	 details	 the	 overall	 findings	 for	 age	 and	 coverage	 of	 vac-
cination	from	all	surveys.	A	total	of	8,562	infants	were	recruited.	
Most	 infants	 (78–83%)	 were	 aged	 4–16	 months	 old	 at	 each	
time	 point.	 Overall	 96.3%	 of	 the	 infants	 had	 health	 passports.	
The	 three-dose	 coverage	 of	 PCV13	 vaccine	 in	 age-eligible	
children	 increased	 from	 10.0%	 in	 March	 2012	 to	 86.0%	 in	
June	2014.	Similarly,	 there	was	also	an	 increase	during	 the	same	
time	 period	 of	 the	 coverage	 of	 PCV13	 doses	 1	 and	 2	 in	 age-	
eligible	 children	 from	 62.0%	 and	 30.3%	 respectively	 in	 March	
2012	 to	93.9%	and	85.2%	by	June	2014.	 In	all	 six	surveys	older	
infants	 (aged	 4–16	 months)	 were	 much	 more	 likely	 to	 be	 vac-
cinated	 (with	 one,	 two	 or	 three	 PCV13	 doses)	 than	 infants	 aged	
less	 than	 4	 months	 old.	 Vaccination	 timeliness	 for	 the	 first,	
second	and	 third	PCV13	doses	 increased	 from	11%,	9%	and	5%	
in	 March	 2012	 to	 47%,	 56%	 and	 48%	 in	 June	 2013	 and	 49%,	
61%	 and	 62%	 in	 June	 2014	 (Table	 1).	The	median	 ages	 at	 first,	
second	 and	 third	 doses	 mirrored	 this	 improvement,	 dropping	
throughout	 the	 six	 surveys	 and	 rapidly	 so	 in	 the	 first	 three	
surveys;	 overall	 they	 were	 9	 weeks	 (interquartile	 range	 (IQR),	
7–13	 weeks),	 15	 weeks	 (IQR,	 12–20	 weeks),	 and	 21	 weeks	
(IQR,	18–27	weeks;	Table	1).
Figure	 2	 shows	 how	 the	 coverage	 of	 the	 first	 two	 doses	 of	
PCV13	 changed	 in	 each	 basin	 from	 the	 first	 survey	 in	 March	
2012	 to	 the	 sixth	 and	 last	 survey	 in	 June	 2014	 in	 6-week	 to	
16-month-old	 babies.	 In	March	 2012,	 all	 but	 one	 (Muyande)	 of	
the	 20	 basins	 had	 a	 two-dose	 coverage	 below	 50%,	 as	 indicated	
by	 the	 confidence	 intervals	 for	 the	 estimated	 coverage	 being	
below,	 or	 overlapping	 50%	 coverage.	 By	 June	 2014	 all	 of	 the	
basins	 had	 coverage	 above	 50%	 and	 eight	 of	 the	 20	 basins	 had	
achieved	 ≥80%	 two-dose	 coverage,	 as	 indicated	 by	 the	 lower	
confidence	 interval	 for	 the	estimated	proportion	vaccinated	being	
above	 80%	 (Figure	 2,	 basins	 in	 order	 of	 June	 2014	 coverage).	
All	 basins	 combined	 were	 also	 estimated	 to	 have	 a	 two-dose	
coverage	above	80%	in	June	2014	(Figure	2).
In	March	 2012	 coverage	 of	 all	 three	 doses	 of	 PCV13	was	more	
than	 95%	 likely	 to	 be	 <40%	 in	 all	 20	 basins	 (Figure	 3).	 By	
June	 2014	 three-dose	 coverage	was	more	 than	 95%	 likely	 to	 be	
≥60%	 in	 all	 20	 basins,	 ≥70%	 in	 16	 basins,	 and	 met	 the	 ≥80%	
local	target	in	11	basins	(Figure	3).
The	 two-dose	 and	 three-dose	 PCV13	 coverage	 was	 consistently	
lower	 in	 6-week	 to	 4-month-old	 infants	 than	 in	 4–16-month-old	
infants	 (Table	 1	 and	 Supplementary	 Figure	 1–Supplementary	
Figure	4).
Figure	 4	 shows	 the	 trend	 for	 the	 overall	 two-dose	 and	 three-
dose	 coverage	 by	 age,	 over-time.	 The	 March	 2012	 survey	
shows	 that	 the	 two-dose	 coverage	 was	 higher	 (≥50%)	 in	 infants	
aged	 6	 and	 7	 months	 old	 but	 lower	 (≤40%)	 in	 infants	 aged	
8–16	months.	The	 two-dose	coverage	 increased	 to	≥90%	 in	 June	
2014	 for	 all	 infants	 aged	 6–16	 months.	 The	 three-dose	 cover-
age	 was	 lower	 (<20%)	 among	 all	 infants	 aged	 6–16	 months	
old	 in	 March	 2012	 but	 increased	 to	 >80%	 by	 October	 2013	
and	 >85%	 by	 June	 2014.	 All	 raw	 data	 associated	 with	 this	
study	are	freely	available	from	the	UK	Data	Service17.
Discussion
Our	 results	 show	 that	 three-dose	 PCV13	 vaccination	 coverage	
in	Kabudula	health	area	met	 the	 local	district	 target	of	≥80%8	by	
the	 second	 year	 of	 the	 vaccination	 campaign,	 but	 only	 in	 older	
infants.	 By	 October	 2012,	 the	 end	 of	 year	 1	 of	 the	 PCV	 vac-
cination	 program	 in	 the	 study	 area,	 the	 survey	 found	 that	 the	
overall	 three-dose	 coverage	 in	 age-eligible	 infants	 was	 at	 64%	
(Infants	<4	months	old:	8%,	Infants	over	4	months	old:	68%),	far	
below	 the	national	 target	of	≥90%	and	 the	 local	district	 target	of	
≥80%8.	 Our	 analysis	 shows	 that	 none	 of	 the	 basins	 had	 three-
dose	 coverage	 of	 ≥80%	 after	 year	 1	 (Supplementary	 Figure	 5).	
The	 three-dose	coverage	 in	age-eligible	 infants	 increased	 to	80%	
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Table 1. Overall results of each and all surveys.
Variable Wave Total
1 
Mar’12
2 
Oct’12
3 
Jun’13
4 
Oct’13
5 
Feb’14
6 
Jun’14
Infants, N 1317 1393 1389 1498 1404 1561 8562
Health passports, % No 7.6% 3.4% 2.7% 4.1% 2.4% 2.2% 3.7%
Yes 92.4% 96.6% 97.3% 95.9% 97.6% 97.8% 96.3%
Age, % <4 months 22.1% 16.2% 18.1% 18.0% 17.6% 17.1% 18.1%
4–16 months 77.9% 83.8% 81.9% 82.0% 82.4% 82.9% 81.9%
Vaccination coverage, 
% (n age-eligible 
respondents^)*
No doses 38.0% (1306)   9.4% (1391) 9.5% (1388) 8.3% (1488) 7.5% (1403) 6.1% (1561)
1 dose 62.0% (1306) 90.6% (1391) 90.5% (1388) 91.7% (1488) 92.5% (1403) 93.9% (1561)
2 doses 30.3% (1215) 81.2% (1313) 85.0% (1312) 83.6% (1407) 86.0% (1324) 85.2% (1491)
3 doses 10.0% (1113) 64.3% (1240) 72.3% (1235) 79.5 (1307)% 82.1% (1233) 86.0% (1384)
Vaccination coverage* 
(n, total respondents&)
No doses 39.0% 9.0% 9.5% 8.4% 7.7% 6.0%
1 dose 61.0% 91.0% 90.5% 91.6% 92.3% 94.0%
2 doses 27.3% 76.9% 80.3% 78.7% 81.2% 82.2%
3 doses 8.5% 57.7% 64.3% 69.8% 72.4% 76.7%
Vaccination coverage 
[<4 months]*, % (n age-
eligible respondents^)*
No doses 43.0% (281) 31.2% (223) 33.2% (250) 29.8% (269) 29.7% (246) 20.6% (267)
1 or more 
doses
56.0% (281) 70.8% (223) 66.8% (250) 70.2% (269) 70.3% (246) 79.4% (267)
2 or more 
doses
19.2% (190) 40.3% (145) 43.1% (174) 32.9% (178) 40.5% (167) 39.9% (197)
3 or more 
doses
  8.6% (88)   8.4% (75)   8.2% (97)   9.4% (78) 16.3% (76) 29.8% (90)
Vaccination coverage 
at 4–16 months, % (n 
total respondents)*
No doses 36.7% (1025)   5.1% (1168)   4.3% (1138)   3.5% (1229)   2.6% (1157)   2.9% (1294)
1 or more 
doses
63.3% (1025) 94.9% (1168) 95.7% (1138) 96.5% (1229) 97.4% (1157) 97.1% (1294)
2 or more 
doses
31.8% (1025) 86.8% (1168) 91.3% (1138) 91.1% (1229) 92.8% (1157) 92.7% (1294)
3 or more 
doses
10.1% (1025) 68.2% (1165) 77.7% (1138) 84.4% (1229) 87.0% (1157) 90.4% (1294)
Timeliness, % Timely 1st 
dose†
11.1% 28.6% 46.7% 45.9% 46.3% 48.9% 38.5%
Timely 2nd 
dose¶
8.5% 33.3% 55.8% 53.7% 55.9% 61.2% 45.5%
Timely 3rd 
dose§
4.9% 29.5% 47.7% 51.1% 53.1% 61.5% 42.1%
All three 
doses 
timely
2.2% 14.2% 27.7% 29.2% 31.1% 35.6% 23.8%
Median age in weeks at 
vaccination, IQR
Dose 1 17.3  
(10.1–32.4)
11.3 
(7.9–17.4)
8.6  
(7.1–11.3)
8.6  
(7.3–10.9)
8.6  
(7.1–11.0)
8.4  
(7.0–10.9)
9.1 
(7.3–
13.0)
Dose 2 22.1  
(15.9–33.7)
18.7  
(14.1–26.9)
14.7  
(12.3–18.3)
14.6  
(12.3–18.3)
14.3  
(12.1–18.6)
14.1  
(12.0–17.3)
15.3 
(12.4–
19.7)
Dose 3 24.1  
(19.1–32.7)
25.5  
(20.0–34.4)
20.9  
(17.4–25.9)
21.0  
(17.9–26.0)
21.0  
(17.4–26.4)
20.4  
(17.3–24.3)
21.3 
(17.9–
26.9)
*Average calculated from all 20 clinic catchment basins, weighted by eligible population size. ^For one-dose coverage infants 6 weeks (42 days) 
or older; for two-dose coverage infants 10 weeks (70 days) or older; For 3 dose coverage infants 14 weeks (98 days) or older. &These coverage 
estimates with the total number of respondents as the denominator (i.e. not just age-eligible infants) are shown for comparison with other estimate that 
do not adjust for age eligibility. †Infants whose first dose of 13-valent pneumococcal conjugate vaccine (PCV13) vaccination took place when they 
were 4 weeks to 2 months old (28 to 60 days old). ¶Infants whose second dose of PCV13 vaccination took place when they were 8 weeks to 4 months 
old (56 to 121 days old). §Infants whose third dose of PCV13 vaccination took place when they were 12 weeks to 6 months old (84 to 182 days old). 
IQR, interquartile range.
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Figure 2. The two-dose coverage of 13-valent pneumococcal conjugate vaccine by lot and survey. Light blue, wave 1 (March 2012); 
dark blue, wave 6 (June 2014). Numbers on the right indicate the estimated coverage at waves 1 and 6. Tick marks indicate one-sided 95% 
confidence interval bounds. Green vertical target lines at 50% (dashed) and 80% (solid).
(infants	 <4	 months	 old,	 9%;	 infants	 over	 4	 months	 old,	 84%)	
by	 the	 end	 of	 year	 2	 (October	 2013	 survey),	 and	 86%	 (infants	
<4	 months	 old:	 30%;	 infants	 over	 4	 months	 old:	 90%)	 by	 June	
2014,	 two-thirds	 through	 year	 3	 (Table	 1).	 In	 total,	 14	 of	 the	
20	 basins	 had	 >80%	 coverage	 in	 4–16-month-olds	 in	 June	 2014	
(Supplementary	Figure	4).
We	 found	 timeliness	 of	 PCV13	 vaccination	 to	 be	 low	 during	
the	 first	 year	 of	 the	 vaccination	 campaign,	 probably	 reflecting	
the	 initial	 catch-up	 campaign	 of	 vaccinating	 all	 infants	 under	
1	 year.	By	 June	2013	we	 found	 that	 around	half	 of	 infants	were	
vaccinated	 within	 the	 standard	 schedule	 for	 each	 dose	 but	 only	
around	 one-quarter	 were	 receiving	 all	 three	 doses	 within	 the	
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Figure 3. The three-dose coverage of 13-valent pneumococcal conjugate vaccine by lot and survey. Light blue, wave 1 (March 2012); 
dark blue, wave 6 (June 2014). Numbers on the right indicate the estimated coverage at waves 1 and 6. Tick marks indicate one-sided 95% 
confidence interval bounds. Green vertical target lines at 50% (dashed) and 80% (solid).
first	 6	months	of	 life	 as	 per	 schedule.	This	 rose	 slightly	by	 June	
2014	 to	 49%	 for	 the	 first	 dose,	 61%	 and	 62%	 for	 the	
second	 and	 third	 doses	 and	 36%	 for	 all	 three	 doses	 (Table	 1).	
This	 is	 lower	 than	 reported	by	a	 recent	 study	 in	Karonga,	which	
found	 ~80%	 of	 eligible	 infants	 were	 vaccinated	 with	 all	 three	
PCV13	 doses	 by	 26	 weeks	 of	 age18.	 Virtually	 all	 (99.8%)	 of	
the	 infants	 who	 were	 not	 vaccinated	 within	 the	 schedule	 were	
vaccinated	 late	 rather	 than	 early.	 Our	 results	 are	 comparable	
to	 the	 findings	 of	 Babirye	 et al.	 in	 Uganda,	 which	 used	 the	
same	 definitions	 of	 timeliness	 for	 the	 three	 doses	 of	 polio	 and	
pentavalent	 vaccination	 but	 found	 greater	 timeliness	 of	 each	
dose	 ranging	 from	 71%	 for	 polio	 1	 to	 78%	 for	 polio	 2	 and	
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pentavalent	 219.	 In	 2004	 Malawi	 was	 found	 to	 have	 52%	
coverage	 of	 DPT3	 (diphtheria-pertussis-tetanus	 vaccination,	
third	dose)	by	6	months	of	age14.
The	 three-doses-within-the-first-6-months	 schedule	 is	 recom-
mended	 in	 settings	 such	 as	 Malawi,	 where	 severe	 vaccine-	
preventable	 disease	 is	 common	 in	 younger	 infants20.	 Existing	
vaccine	 schedules	 at	 6,	 10	 and	 14	 weeks,	 such	 as	 those	 for	
polio	 and	 pentavalent	 vaccine	 also	 make	 it	 logistically	 easier20.	
Delayed	 vaccination	 extends	 individual	 susceptibility	 to	 illness	
and	 reduces	 herd	 immunity21.	 However,	 whether	 an	 initial	 two-
dose	 plus	 booster	 (2+1),	 initial	 three-dose	 (3+0)	 or	 a	 three-dose	
plus	 booster	 (3+1)	 schedule	 is	 better	 at	 preventing	 clinical	
pneumonia	 remains	 unresolved22.	A	 recent	 trial	 in	 South	Africa,	
which	 has	 similar	 pneumonia	 epidemiology	 to	 Malawi,	 found	
a	 2+1	 PCV	 schedule	 of	 6,	 14,	 38	 weeks	 to	 significantly	 reduce	
IPD4.
There	 are	 some	 limitations	 to	 this	 study.	 Firstly,	 the	 sample	
size	 for	 the	 infants	 aged	 6	 weeks	 to	 4	 months	 was	 less	 than	
half	 of	 the	 intended	 sample	 of	 600	 infants	 (30	 per	 basin)	 for	 all	
the	 surveys	 conducted.	 This	 was	 due	 to	 there	 being	 insufficient	
infants	 of	 this	 age	 group	 in	 each	 basin	 at	 the	 time	 of	 survey.	
However,	 given	 the	 low	 numbers	 who	 were	 vaccinated	 and	 the	
high	 probability	 of	 low	 coverage	 thresholds	 not	 being	met	 given	
the	 estimated	 confidence	 intervals,	 we	 can	 be	 fairly	 sure	 that	
the	 coverage	 was	 low	 in	 this	 age	 group.	 Secondly,	 the	 self-
weighted	 analysis	 here	 implicitly	 assumes	 that	 every	 eligible	
respondent	 had	 the	 same	 chance	 of	 being	 selected,	 but	 this	 is	
not	 so	 in	 this	 case,	 as	 the	 interviewers	 always	 started	 at	 the	
centre	 of	 the	 village.	 Furthermore,	 for	 confidence	 intervals	 to	
be	 meaningful,	 the	 sample	 should	 be	 a	 probability	 sample	 and	
the	 analysis	 should	 incorporate	 appropriate	 sampling	 weights.	
This	 simple	 self-weighted	 analysis	 of	 a	 somewhat	 biased	
sample	 may	 not	 meet	 the	 strict	 requirements	 for	 confidence	
intervals.	 However,	 the	 six	 surveys	 used	 the	 same	 method	 of	
data	 collection	 each	 time,	 so	 the	 biases	 over	 time	 are	 likely	 to	
be	 constant.	 The	 coverage	 results	 also	 improved	 so	 dramati-
cally	over	 time	 that	our	broad-stroke	conclusions	are	 likely	 to	be	
robust.	The	villages	are	small	and	a	 large	proportion	of	 the	eligi-
ble	 children	 were	 sampled	 in	 each	 village	 so	 the	 improvements	
in	 coverage	 and	 the	 persistent	 shortfalls	 in	 timeliness	 described	
here	 are	 likely	 to	 be	 real,	 although	 subject	 to	 bias.	 Thirdly,	 due	
to	a	 large	proportion	of	eligible	children	being	surveyed	 in	some	
basins,	 some	 of	 the	 same	 children	 in	 the	 older	 4–16-months	
age	 group	 may	 have	 been	 sampled	 in	 more	 than	 one	 survey,	
introducing	 some	 correlation	 to	 the	 repeated	 cross-sectional	
samples,	 meaning	 our	 assessment	 of	 trends	 in	 vaccine	 coverage	
may	be	 less	 representative	of	 the	overall	 trend	 in	 the	population.	
This	 is	 likely	 to	 be	 a	 minor	 issue	 given	 that	 the	 surveys	 were	
4–8	 months	 apart.	 Fourthly,	 the	 studies	 were	 only	 conducted	
in	 one	 of	 the	 six	 health	 areas	 of	 Lilongwe	 district;	 therefore	
the	 results	 may	 not	 be	 generalizable,	 unless	 compared	 with	
other	 studies	 carried	 out	 during	 the	 same	 period	 in	 other	
parts	 of	 the	 country.	 Kabudula	 is	 however,	 fairly	 representa-
tive	 of	 rural	 Lilongwe	 district	 and	 Malawi	 in	 general,	 being	
found	to	have	vaccination	rates	around	the	average	for	 the	whole	
country	 in	 2007,	 although	 variation	 in	 local	 vaccine	 stocks	 and	
logistics	 is	 an	 important	 consideration23.	 Fifthly,	 although	 96%	
of	 infants	 had	 vaccination	 data	 photographed	 from	 health	 pass-
ports,	meaning	 the	potential	of	 recall	 bias	 to	 affect	our	 results	 is	
low,	 there	 were	 a	 few	 anecdotal	 reports	 of	 vaccination	 records	
being	 filled	 before	 vaccinations	 were	 administered.	 Vaccine	
stock-outs	 at	 clinics	 or	 health	 facilities	 mean	 it	 was	 possi-
ble	 that	 a	 health	 passport	 could	 indicate	 vaccination	 when	 the	
infant	 was	 not	 vaccinated.	 From	 discussions	 with	 health	 facility	
and	 immunization	 staff,	 we	 were	 assured	 that	 this	 was	 a	
relatively	 rare	 occurrence.	 Mothers	 also	 verbally	 verified	 their	
infants	 were	 vaccinated	 in	 almost	 all	 cases	 where	 vaccination	
was	 indicated	 on	 the	 infant’s	 health	 passport.	 Finally,	 tracking	
coverage	 in	each	basin	can	be	difficult—the	 same	basins	did	not	
always	 have	 lower	 coverage	 (Supplementary	 Figure	 5),	 likely	
due	 to	 changing	 community	 and	 health-system	 dynamics,	 as	
well	 as	 due	 to	 artefacts	 of	 the	 relatively	 small	 sample	 sizes	 in	
each	basin.
Before	 the	 advent	 of	 PCV13,	 it	 was	 estimated	 that	 PCV13	
would	 protect	 against	 63%	 of	 all	 circulating	 invasive	
Figure 4. Trends in two-dose and three-dose coverage of 13-valent pneumococcal conjugate vaccine by age in months.
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pneumococci	 and	 78%	 of	 those	 found	 in	 children	 under	 5	 years	
in	 Malawi24.	 We	 previously	 published	 that	 at	 76%	 three-dose	
PCV13	 coverage,	 compared	 to	 0%	 three-dose	 coverage,	 and	
among	 children	 <59	months	 of	 age,	 cases	 of	 pneumonia	 associ-
ated	with	low	oxygen	levels	(i.e.,	hypoxemia)	decreased	by	nearly	
50%	 and	 hospital	 pneumonia	 fatalities	 declined	 by	 more	 than	
one-third	 in	 central	 Malawi9.	 Furthermore,	 the	 proportion	 of	
pneumonia	 cases	 with	 clinical	 danger	 signs	 associated	 with	
high	 risk	 of	 mortality	 fell	 by	 nearly	 two-thirds	 in	 Malawi	
after	the	introduction	of	PCV139.
Conclusion
Meeting	 and	maintaining	 the	 90%	PCV13	 coverage	 target	 in	 all	
areas	 of	 Malawi	 in	 the	 coming	 months	 and	 years,	 and	 improv-
ing	 the	 timeliness	 of	 vaccination	 in	 young	 infants,	 has	 great	
potential	 to	 reduce	 the	 burden	 of	 PCV13-preventable	 disease.	
Monitoring	 the	 progress	 towards	 this	 goal	 via	 household	
surveys	of	PCV13	coverage	is	important.
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Expanded Programme on Immunization (EPI), Department of Immunization, Vaccines and Biologicals
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This paper presents the results of surveys done to track uptake of pneumococcal conjugate vaccine
(PCV) in rural areas in Malawi. It is well written, the results are clear, and the limitations well
acknowledged. All figures are very useful, and particularly Figure 1 provides a great visual to understand
survey implementation.
 
Specific comments 
 
Title
Consider adding “in selected areas in rural Malawi” to give a clear message that these surveys are
not representative of the entire country
 
Introduction
Pneumococcal in pneumococcal conjugate vaccines does not need to be capitalized
The bacteria for which there is a vaccine is   type b (Hib) – small b.Haemophilus influenzae
In the first paragraph, consider citing the WHO Position Paper on Pneumococcus vaccines
(available at:  ), insteadhttp://www.who.int/immunization/policy/position_papers/pneumococcus/en/
of, or in addition to, current reference 3.
In the second paragraph, consider indicating that the target coverage rates are aligned with the
Global Vaccine Action Plan (GVAP), available at: 
http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/
 
Methods
Include a clearer definition of “timely vaccination”. In the results, we learned what it was mainly in
the footnote of Table 1.
There is no “standard WHO Schedule” per se, see 
. The one used in Malawi is one ofhttp://www.who.int/immunization/policy/immunization_tables/en/
the schedules frequently used in African and other low and middle-income countries, but it is not
the WHO recommended schedule per se, for example, for measles WHO recommends 9 or 12
months depending on the epidemiological situation, same for including or not an OPV0. I suggest
rewording and reconsidering reference 14. It can be indicated that this is “the Malawi vaccination
schedule”. To my knowledge, there is no one accepted definition of “timeliness” (see for example
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schedule”. To my knowledge, there is no one accepted definition of “timeliness” (see for example
Tauil et al. ) Furthermore, Clark and Sanderson looked at inverse surviving curves and impute
dates to those without cards, which I don’t think was the case in this study.
Under analysis, we learned that a finite population correction was used, based on an estimate of
the eligible population, what is the source of this population data and year?
Under ethical approval, were there any specific precautions taken to maintain confidentiality in
relation to the pictures of health passports?
 
Results
In Table 1, consider proving the availability of health passports by age group, given that it is more
likely that they were available for younger infants
In Figure 4, it is unclear who is in the denominator, all infants or those with documented dates?
 
Discussion
The first paragraph talks about a “vaccination campaign”, this seems misleading as, if I understand
correctly, PCV vaccine was included into routine immunization and not given using a
campaign-type strategy.
Consider adding the WHO Position Paper on Pneumococcus vaccines (available at: 
), instead of, or inhttp://www.who.int/immunization/policy/position_papers/pneumococcus/en/
addition to, current reference 20.
Is there information to describe how PCV vaccine coverage compares to coverage for other
vaccines recommended at the same age (DTp-Hib-HepB, OPV)? It would be useful to better
understand if PCV vaccine uptake behaves like the others or not.
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